Is XBiotech Stock a Good Investment?
XBiotech Investment Advice | XBIT |
- Examine XBiotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research XBiotech's leadership team and their track record. Good management can help XBiotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact XBiotech's business and its evolving consumer preferences.
- Compare XBiotech's performance and market position to its competitors. Analyze how XBiotech is positioned in terms of product offerings, innovation, and market share.
- Check if XBiotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about XBiotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in XBiotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if XBiotech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine XBiotech Stock
Researching XBiotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 35.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.17. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XBiotech recorded a loss per share of 1.08. The entity last dividend was issued on the 15th of July 2021.
To determine if XBiotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XBiotech's research are outlined below:
| XBiotech had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 300 K. Net Loss for the year was (24.56 M) with profit before overhead, payroll, taxes, and interest of 3.36 M. | |
| XBiotech currently holds about 225.79 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| XBiotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by insiders | |
| Latest headline from MacroaxisInsider: Disposition of 12308 shares by Han Queena of XBiotech at 4.16 subject to Rule 16b-3 |
XBiotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XBiotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XBiotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of January 2024 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact XBiotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises XBiotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-08-12 | 2016-06-30 | -0.35 | -0.42 | -0.07 | 20 | ||
2016-05-13 | 2016-03-31 | -0.39 | -0.32 | 0.07 | 17 | ||
2022-03-02 | 2021-12-31 | 0.02 | -0.06 | -0.08 | 400 | ||
2016-11-14 | 2016-09-30 | -0.46 | -0.38 | 0.08 | 17 | ||
2021-08-13 | 2021-06-30 | 0.03 | -0.06 | -0.09 | 300 | ||
2017-03-16 | 2016-12-31 | -0.42 | -0.51 | -0.09 | 21 | ||
2021-05-12 | 2021-03-31 | 0.04 | -0.06 | -0.1 | 250 | ||
2021-03-16 | 2020-12-31 | 0.04 | -0.06 | -0.1 | 250 |
Know XBiotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XBiotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XBiotech backward and forwards among themselves. XBiotech's institutional investor refers to the entity that pools money to purchase XBiotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 77.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 72.5 K | Empowered Funds, Llc | 2024-06-30 | 69.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 58.4 K | Fmr Inc | 2024-09-30 | 29 K | Nuveen Asset Management, Llc | 2024-06-30 | 24.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 23.6 K | Rhumbline Advisers | 2024-06-30 | 20.1 K | Citigroup Inc | 2024-09-30 | 14.5 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 1.1 M |
XBiotech's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 224.05 M.Market Cap |
|
XBiotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.11) | (0.11) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.11) | (0.11) | |
| Return On Equity | (0.11) | (0.12) |
Determining XBiotech's profitability involves analyzing its financial statements and using various financial metrics to determine if XBiotech is a good buy. For example, gross profit margin measures XBiotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of XBiotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in XBiotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XBiotech. Check XBiotech's Beneish M Score to see the likelihood of XBiotech's management manipulating its earnings.
Evaluate XBiotech's management efficiency
XBiotech has return on total asset (ROA) of (0.1203) % which means that it has lost $0.1203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1575) %, meaning that it created substantial loss on money invested by shareholders. XBiotech's management efficiency ratios could be used to measure how well XBiotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2024. Return On Capital Employed is likely to drop to -0.18 in 2024. Total Current Liabilities is likely to gain to about 9.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 209.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.22 | 4.35 | |
| Tangible Book Value Per Share | 7.22 | 4.48 | |
| Enterprise Value Over EBITDA | 2.20 | 2.31 | |
| Price Book Value Ratio | 0.55 | 0.53 | |
| Enterprise Value Multiple | 2.20 | 2.31 | |
| Price Fair Value | 0.55 | 0.53 | |
| Enterprise Value | -58 M | -55.1 M |
The operational strategies employed by XBiotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.413 |
Basic technical analysis of XBiotech Stock
As of the 29th of November, XBiotech maintains the Downside Deviation of 5.26, market risk adjusted performance of 0.111, and Mean Deviation of 3.58. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of XBiotech, as well as the relationship between them.XBiotech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XBiotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on XBiotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases XBiotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
XBiotech's Outstanding Corporate Bonds
XBiotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XBiotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XBiotech bonds can be classified according to their maturity, which is the date when XBiotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand XBiotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing XBiotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0566 | |||
| Market Risk Adjusted Performance | 0.111 | |||
| Mean Deviation | 3.58 | |||
| Semi Deviation | 4.59 | |||
| Downside Deviation | 5.26 | |||
| Coefficient Of Variation | 1589.58 | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.78 | |||
| Information Ratio | 0.0366 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.43) | |||
| Sortino Ratio | 0.0332 | |||
| Treynor Ratio | 0.101 | |||
| Maximum Drawdown | 24.03 | |||
| Value At Risk | (7.91) | |||
| Potential Upside | 7.61 | |||
| Downside Variance | 27.68 | |||
| Semi Variance | 21.05 | |||
| Expected Short fall | (3.66) | |||
| Skewness | (0.47) | |||
| Kurtosis | 0.8921 |
| Risk Adjusted Performance | 0.0566 | |||
| Market Risk Adjusted Performance | 0.111 | |||
| Mean Deviation | 3.58 | |||
| Semi Deviation | 4.59 | |||
| Downside Deviation | 5.26 | |||
| Coefficient Of Variation | 1589.58 | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.78 | |||
| Information Ratio | 0.0366 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.43) | |||
| Sortino Ratio | 0.0332 | |||
| Treynor Ratio | 0.101 | |||
| Maximum Drawdown | 24.03 | |||
| Value At Risk | (7.91) | |||
| Potential Upside | 7.61 | |||
| Downside Variance | 27.68 | |||
| Semi Variance | 21.05 | |||
| Expected Short fall | (3.66) | |||
| Skewness | (0.47) | |||
| Kurtosis | 0.8921 |
Consider XBiotech's intraday indicators
XBiotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of XBiotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
XBiotech Corporate Filings
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 21st of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 1st of May 2024 An amendment to a previously filed Form 10-K | ViewVerify |
XBiotech Stock media impact
Far too much social signal, news, headlines, and media speculation about XBiotech that are available to investors today. That information is available publicly through XBiotech media outlets and privately through word of mouth or via XBiotech internal channels. However, regardless of the origin, that massive amount of XBiotech data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of XBiotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of XBiotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to XBiotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive XBiotech alpha.
XBiotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards XBiotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
XBiotech Corporate Management
| Benjamn Guzmn | Sr Fin | Profile | |
| Angela Hu | Principal Finance | Profile | |
| Lisa Simard | Inc USA | Profile | |
| Sushma Shivaswamy | Chief Officer | Profile | |
| BA CGA | VP Sec | Profile |
Already Invested in XBiotech?
The danger of trading XBiotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XBiotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XBiotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XBiotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.